First-of-its-Kind skin ointment aims to treat rare genetic disease at its source
NCT ID NCT06137157
Summary
This is the first human study to test a new topical ointment, ATR12-351, designed to treat the underlying cause of Netherton Syndrome. The trial will enroll about 12 adults to check if the ointment is safe and well-tolerated when applied to skin lesions twice daily for two weeks. Researchers will compare treated skin to untreated skin on the same person to see if the treatment helps.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale University
COMPLETEDNew Haven, Connecticut, 06519, United States
Conditions
Explore the condition pages connected to this study.